<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899261</url>
  </required_header>
  <id_info>
    <org_study_id>2010-326</org_study_id>
    <secondary_id>2010-326</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01899261</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies stereotactic body radiation therapy in treating patients&#xD;
      with liver cancer that cannot be removed by surgery. Stereotactic radiation therapy may be&#xD;
      able to send x-rays directly to the tumor and cause less damage to normal tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate feasibility and safety of stereotactic body radiation therapy (SBRT) of the&#xD;
      liver for treatment of hepatocellular carcinoma (HCC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate radiographic local response, local control and time to local progression&#xD;
      (TTLP) of treated lesions in HCC patients after liver SBRT.&#xD;
&#xD;
      II. To evaluate overall survival (OS) and cancer specific survival (CSS) in HCC patients&#xD;
      treated with liver SBRT.&#xD;
&#xD;
      III. To evaluate explanted irradiated liver tissue (for patients who proceed to liver&#xD;
      transplantation) to determine extent of residual tumor and extent of radiation effects within&#xD;
      and around the irradiated field.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months&#xD;
      and then every 6 months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2010</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe Treatment-related Toxicity</measure>
    <time_frame>Within 3 months of SBRT</time_frame>
    <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSS</measure>
    <time_frame>Time from study entry to death from HCC progression, assessed up to 2 years</time_frame>
    <description>Competing risk analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time from study entry to death from any cause, assessed up to 2 years</time_frame>
    <description>Estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate Defined as Proportion of Patients Achieving a Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 6 months after completion of SBRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTLP</measure>
    <time_frame>Time from study entry to radiographic local progression based on RECIST, assessed up to 2 years</time_frame>
    <description>Estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adult Hepatocellular Carcinoma</condition>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <condition>Localized Non-Resectable Adult Liver Carcinoma</condition>
  <condition>Recurrent Adult Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>stereotactic external-beam radiation therapy</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
    <other_name>stereotaxic radiation therapy</other_name>
    <other_name>stereotaxic radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  HCC diagnosed by either of the following approaches:&#xD;
&#xD;
               -  Histologic confirmation of HCC on biopsy&#xD;
&#xD;
               -  Evidence of vascular enhancement of suspected lesion on at least two imaging&#xD;
                  techniques&#xD;
&#xD;
               -  Evidence of vascular enhancement on a single technique if the alpha-fetoprotein&#xD;
                  (AFP) is &gt; 200 ng/mL in the setting of cirrhosis or chronic hepatitis B/C&#xD;
&#xD;
          -  HCC must be deemed unresectable by an experienced surgeon or patient must be medically&#xD;
             inoperable or extra-hepatic metastases must be present (making resection an&#xD;
             inappropriate treatment option) or patient must have declined the option of surgery&#xD;
             after consultation with a surgeon&#xD;
&#xD;
               -  Barcelona Clinic Liver Cancer score of B or C required (i.e., intermediate or&#xD;
                  advanced stage HCC)&#xD;
&#xD;
          -  Prior liver resection or ablative therapy is permitted&#xD;
&#xD;
          -  Prior transarterial chemoembolization (TACE) is permitted&#xD;
&#xD;
          -  Patients must have recovered from the effects of previous therapy&#xD;
&#xD;
          -  Maximal tumor size of 15 cm and &gt; 700 cc of uninvolved liver&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/L&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1.0 bil/L&#xD;
&#xD;
          -  Platelets &gt;= 70,000 bil/L&#xD;
&#xD;
          -  Total bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 1.5 or correctable with vitamin K (higher INR&#xD;
             acceptable if patient is on Coumadin)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 6 times upper&#xD;
             range of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis or encephalopathy related to liver failure&#xD;
&#xD;
          -  Prior radiation therapy to the upper abdomen or thorax&#xD;
&#xD;
          -  Lesions within 1 cm from the stomach&#xD;
&#xD;
          -  Prior uncontrolled, life threatening malignancy within the previous 6 months&#xD;
&#xD;
          -  Pregnancy is not permitted; women of child-bearing age must undergo pregnancy testing&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Previous gastric, duodenal or variceal bleed within the past 2 months&#xD;
&#xD;
          -  Thrombolytic therapy within 4 weeks or commencement of anticoagulant use within the&#xD;
             past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitin Ohri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Nitin Ohri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.&#xD;
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.&#xD;
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="55" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>The Child-Pugh score employs five clinical measures of liver disease: total bilirubin, serum albumin, prothrombin time, ascites, and hepatic encephalopathy. Each measure is scored 1-3, with 3 indicating most severe derangement. The total score therefore ranges from 5 to 15.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severe Treatment-related Toxicity</title>
        <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
        <time_frame>Within 3 months of SBRT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (SBRT)</title>
            <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.&#xD;
Stereotactic Radiosurgery: Undergo SBRT</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Treatment-related Toxicity</title>
          <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSS</title>
        <description>Competing risk analysis will be performed.</description>
        <time_frame>Time from study entry to death from HCC progression, assessed up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS</title>
        <description>Estimated by the Kaplan-Meier method.</description>
        <time_frame>Time from study entry to death from any cause, assessed up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate Defined as Proportion of Patients Achieving a Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <time_frame>Up to 6 months after completion of SBRT</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTLP</title>
        <description>Estimated by the Kaplan-Meier method.</description>
        <time_frame>Time from study entry to radiographic local progression based on RECIST, assessed up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.&#xD;
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 1 thrombocytopenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1 nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Grade 1 abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1 fatigue</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Grade 1 dermatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nitin Ohri</name_or_title>
      <organization>Montefiore Medical Center and Albert Einstein College of Medicine</organization>
      <phone>718-920-7750</phone>
      <email>nohri@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

